HOME   
   NEWS   
   BUSINESS   
   CRICKET   
   SPORTS   
   MOVIES   
   NET GUIDE   
   SHOPPING   
   BLOGS  
   ASTROLOGY  
   MATCHMAKER  


Search:



The Web

Rediff








Business
Portfolio Tracker
Business News
Specials
Columns
Market Report
Mutual Funds
Interviews
Tutorials
Message Board
Stock Talk
Press Releases



Home > Business > Stock Market News > Hot Pursuits

Dabur dabbles in gains on restructuring initiative

June 02, 2003 14:46 IST

Dabur India edged up today extending the recent rally in the stock.

The scrip of the pharmaceuticals major edged up 2.6% to Rs 46 on BSE. It hit a high of Rs 47.05, earlier. The stock rose on decent volumes of over 2 lakh shares.

The stock has witnessed some revival on the bourses in the last few trading sessions after it experienced a sustained fall over the last few months. From Rs 36.25 on 8 May 2003, the stock has surged 26.8% in less than a month to the current Rs 46.

Analysts have turned positive on the stock on the back of company's restructuring initiatives. In a recent reports, investment bank J M Morgan Stanley has upgraded the stock to overweight with a price target of Rs 52.

Dabur has undertaken restructuring of its operations which comprises of de-merger of the pharma business into a separate company. Thus, Dabur India would become a pure FMCG company from now on. As per the restructuring proposal, one share of the de-merged pharma company will be issued for every two existing shares of Dabur India. The de-merged pharma company will be listed as a separate company.

With this move, Dabur India's business will include personal care products, healthcare products, and ayurvedic specialities. Personal care and health care products such as hair care, oral care, tonics, digestives, child care, ayurvedic medicines and other ayurvedic products, veterinary medicines, and guar gum will come under the umbrella of the FMCG business, while the pharmaceuticals business will include allopathic and oncology formulations, and bulk drugs.

Analysts feel that following the de-merger of the pharma business, the diversion of cash from the consumer division to the pharma division will come to an end.

Also on the flip side, Dabur has significantly improved its balance sheet profile with debt reduction, improvement in working capital management and impairment of fixed assets. Dabur repaid Rs 100 crore of debt in FY 2002-03, resulting in a decline in its debt/equity ratio from 51% to 27% .

Dabur turned out an improved financial performance for FY 2003. It reported a 32% growth in net profit to Rs 85.10 crore on a 6% rise in sales to Rs 1,232.30 crore.

Source: www.capitalmarket.com

Intra-Day Market Report



Article Tools

Email this Article

Printer-Friendly Format

Letter to the Editor




People Who Read This Also Read


Vineeta Rai: New revenue secy

Stanford: Talk on India reforms

Software, IT services exports up







HOME   
   NEWS   
   BUSINESS   
   CRICKET   
   SPORTS   
   MOVIES   
   NET GUIDE   
   SHOPPING   
   BLOGS  
   ASTROLOGY  
   MATCHMAKER  
© 2003 rediff.com India Limited. All Rights Reserved.